Kitcyl 200 Tablet contains Ketoconazole 200mg, an imidazole antifungal agent indicated for the treatment of various fungal infections. Ketoconazole exerts its therapeutic effect by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. Kitcyl 200 is primarily utilized in the management of systemic and superficial mycoses, including candidiasis, dermatophytosis, and pityriasis versicolor. It is also effective against infections caused by dermatophytes, yeasts, and certain molds. The tablet formulation allows for convenient oral administration, facilitating systemic absorption and distribution to infected tissues. Dosage and duration of therapy should be tailored according to the type and severity of infection, and treatment should be continued for an appropriate period to prevent relapse. Caution is advised in patients with hepatic impairment due to potential hepatotoxicity associated with Ketoconazole. Common adverse effects may include gastrointestinal disturbances, headache, and rash. Concomitant use with drugs metabolized by CYP3A4 should be monitored closely to avoid drug interactions. Kitcyl 200 Tablet should be prescribed under medical supervision, ensuring appropriate diagnosis and monitoring for efficacy and safety.